GPT and neoplasm: Additionally, GM101+SBHA or GM101+MS-275 combination therapy did not elevate liver (ALT/AST) and kidney (BUN/CRE) serum toxicity markers compared to those of PBS-treated mice in A549 tumor-bearing mice (Figure S7), demonstrating that the combination therapy can be administered safely without additional risk of toxicity.